<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00017342</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068679</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <secondary_id>MCV-MCC-4710</secondary_id>
    <secondary_id>NCI-4710</secondary_id>
    <nct_id>NCT00017342</nct_id>
  </id_info>
  <brief_title>Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia</brief_title>
  <official_title>Phase II Study Of Bryostatin 1 (NSC 339555) And High-Dose 1-B-D-Arabinofuranosylcytosine (HiDAC) In Patients With Refractory Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining bryostatin 1 with cytarabine&#xD;
      in treating patients who have relapsed primary acute myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with primary acute myelogenous leukemia in first&#xD;
           relapse treated with bryostatin 1 and high-dose cytarabine.&#xD;
&#xD;
        -  Determine the toxic effects of this regimen in these patients.&#xD;
&#xD;
        -  Determine the relapse-free survival and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Induction: Patients receive bryostatin 1 IV over 24 hours on days 1 and 11. Patients&#xD;
           also receive high-dose cytarabine IV over 3 hours every 12 hours for 4 infusions on days&#xD;
           2-3 and days 9-10.&#xD;
&#xD;
      Patients who achieve a major response receive a second course of induction therapy.&#xD;
&#xD;
        -  Consolidation: Patients who achieve complete remission receive bryostatin 1 IV over 24&#xD;
           hours on days 1 and 10 and high-dose cytarabine IV over 3 hours every 12 hours for 2&#xD;
           infusions on days 2 and 9. Treatment continues for up to 6 courses in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who achieve a response and subsequently relapse may receive additional induction and&#xD;
      consolidation therapy at the discretion of the investigator.&#xD;
&#xD;
      Patients are followed every 6 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-46 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bryostatin 1</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary acute myelogenous leukemia (AML) in first relapse&#xD;
             after a remission of at least 3 months duration&#xD;
&#xD;
          -  No secondary AML, including the following:&#xD;
&#xD;
               -  Therapy-related AML&#xD;
&#xD;
               -  AML arising from myelodysplastic syndromes or similar hematological conditions&#xD;
&#xD;
          -  No Philadelphia chromosome or other evidence of a (9;21) translocation&#xD;
&#xD;
          -  Ineligible for potentially curative allogeneic stem cell transplantation&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Zubrod 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN) (patients with&#xD;
             Gilbert's disease or unconjugated hyperbilirubinemia may have bilirubin no greater&#xD;
             than 3.0 mg/dL with conjugated bilirubin no greater than 0.5 mg/dL)&#xD;
&#xD;
          -  AST/ALT no greater than 2 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No clinically significant pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No clinically significant cytarabine-related cerebellar toxicity&#xD;
&#xD;
          -  No nonmalignant systemic disease that causes poor medical risk&#xD;
&#xD;
          -  No active, uncontrolled, serious infection&#xD;
&#xD;
          -  No medical condition that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior allogeneic stem cell transplantation&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 2 weeks since prior systemic chemotherapy (24 hours for hydroxyurea) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grant, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Weill Cornell Cancer Center at Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massey Cancer Center at Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>June 6, 2001</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>February 26, 2010</last_update_submitted>
  <last_update_submitted_qc>February 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven Grant, MD</name_title>
    <organization>Virginia Commonwealth University</organization>
  </responsible_party>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bryostatin 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

